Cachectina/factor de necrosis tumoral El factor de necrosis tumoral es el mismo.

Same author

Is There More than One Erythropoietin Receptor? Can the Hematopoietic Effects of EPO Be Dissociated from the Organ-Protective Effects by Carbamylated Erythropoietin?: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305: 239-242, 2004.

Journal of the American Society of Nephrology : JASN·2023

Same author

Managing chronic inflammation in the aging diabetic patient with CKD by diet or sevelamer carbonate: a modern paradigm shift.

The journals of gerontology. Series A, Biological sciences and medical sciences·2012

Same author

The unexpected pathway to the creation of the HbA1c test and the discovery of AGE's.

Journal of internal medicine·2012

Same author

The value of failure: the discovery of TNF and its natural inhibitor erythropoietin.

Journal of internal medicine·2010

Same author

Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response.

Journal of internal medicine·2008

Same author

Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise.

Kidney international·2006

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

Videos de Experimentos Relacionados

Cachectina/factor de necrosis tumoral El factor de necrosis tumoral es el mismo.

Videos de Conceptos Relacionados

Is There More than One Erythropoietin Receptor? Can the Hematopoietic Effects of EPO Be Dissociated from the Organ-Protective Effects by Carbamylated Erythropoietin?: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305: 239-242, 2004.

Managing chronic inflammation in the aging diabetic patient with CKD by diet or sevelamer carbonate: a modern paradigm shift.

The unexpected pathway to the creation of the HbA1c test and the discovery of AGE's.

The value of failure: the discovery of TNF and its natural inhibitor erythropoietin.

Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response.

Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Videos de Experimentos Relacionados

Cachectina/factor de necrosis tumoral El factor de necrosis tumoral es el mismo.

Videos de Conceptos Relacionados

Artículos Relacionados

Is There More than One Erythropoietin Receptor? Can the Hematopoietic Effects of EPO Be Dissociated from the Organ-Protective Effects by Carbamylated Erythropoietin?: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305: 239-242, 2004.

Managing chronic inflammation in the aging diabetic patient with CKD by diet or sevelamer carbonate: a modern paradigm shift.

The unexpected pathway to the creation of the HbA1c test and the discovery of AGE's.

The value of failure: the discovery of TNF and its natural inhibitor erythropoietin.

Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response.

Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.